Roburic Acid as a Therapeutic Candidate: Antiproliferative Activity and Secondary Cell Death Response in Colorectal Cancer Cells.

Adrianna Gielecińska, Mateusz Kciuk, Renata Gruszka, Sebastian Wawrocki, Renata Kontek

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adrianna GielecińskaDepartment of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.ORCID 0000-0001-9562-3582

Mateusz KciukDepartment of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.ORCID 0000-0002-8616-3825

Renata GruszkaDepartment of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.

Sebastian WawrockiLaboratory of Microscopic Imaging and Specialized Biological Techniques, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.ORCID 0000-0002-1834-4739

Renata KontekDepartment of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.ORCID 0000-0003-2859-9839

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural compounds are increasingly recognized as valuable sources of pharmacologically active agents for cancer therapy. Among them, plant-derived triterpenoids attract attention due to their structural diversity and broad biological activity. Roburic acid (RA), a tetracyclic triterpenoid, has previously been shown to exert antiproliferative effects in colorectal cancer (CRC) cells with limited cytotoxicity. In the present study, we investigated the cellular mechanisms underlying RA activity in CRC cells, focusing on cell cycle regulation, mitochondrial function, apoptosis, oxidative stress, and DNA integrity. RA treatment markedly suppressed CRC cell proliferation, resulting in G

Indexed as

Antineoplastic AgentsCell ProliferationColorectal NeoplasmsApoptosisCell Cycle CheckpointsCell DeathCell Line, TumorChrysenesHumansMembrane Potential, MitochondrialMitochondriaOxidative StressReactive Oxygen SpeciesAntineoplastic AgentsChrysenesReactive Oxygen Speciesroburic acidanti-proliferative activitycell cycle arrestcolorectal cancercytostatic activitymitochondrial dysfunctionroburic acid

Identifiers

PMID41828694

DOI10.3390/ijms27052478

PMCPMC12986222

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.